Through an unbiased proteomic screen of parental and lenvatinib-resistant HCC cells, two key tRNA m7 G methyltransferase complex components, METTL1 and WDR 4, were found to be significantly up-regulated in Lenvatinib-resistant HCC cells, with METTL1 being the catalytic enzyme and WDR 4 acting as a regulator. Here, METTL1 is linked to hepatocellular carcinoma.